Inés Gasén was diagnosed with breast cancer during her pregnancy – not only naturally provoking fear and uncertainty for her…

Taking place on Monday 08 September 2014, beginning with a Welcome coffee at 14:15 – 14:30, followed by the main…

ESMO welcomes the adoption of the Clinical Trials Regulation by the European Union Source: The European Society for Medical Oncology…

VHIO is delighted to announce that Charles M. Perou, May Goldman Shaw Distinguished Professor of Molecular Oncology, professor of genetics,…

Findings presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 – June 03, Chicago IL, USA, reveal that HER2+ breast cancer patients expressing high protein levels respond better to targeted therapy and survive longer.

Presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 – June 03, Chicago IL, USA, the Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) have participated in an international phase III study published in the New England Journal of Medicine. Findings show that the administration of the drug enzalutamide prior to chemotherapy in metastatic prostate cancer patients reduces disease progression of by 81% — consequently postponing initiation of treatment with the latter, and leading to increased survival and improved quality of life for patients.

 • An international study, with the participation of over 500,000 women, reveals that women who are married when diagnosed with breast cancer have a better chance of survival, regardless of tumor characteristics

• The study, in which the Vall d´Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO) have participated, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)

A special study visit was jointly organized by the Centre of Genomic Regulation (CRG) and the European Molecular Biology Laboratory (EMBL) as partners of the EU CommHERE Communicating European Health Research Network, in collaboration with the European Union of Science Journalists’ Associations (EUSJA)
 

This year´s annual Fero Foundation (Fundación de Investigación Oncológica) Grant for Translational Research, amounting to 70,000 EUR was presented Monday 12 May, to Sandra Peiró for a two year research project aimed at determining the three-dimensional structure of the tumor cell genome with emphasis on tumor progression and metastatis.

• The Bioinformatics Barcelona (BIB) platform, a joint initiative of the Government of Catalonia and the Welfare Projects Division of the “la Caixa” Foundation, comprises more than 40 organisations including universities, research centers of excellence, and companies.

• Bioinformatics Barcelona (BIB) aims to become an international reference in promoting multidisciplinary research, training, and technology transfer in bioinformatics.

Barcelona, April 11, 2014. Preclinical, translational and clinical researchers and physician-scientists from the Vall d’Hebron Institute of Oncology (VHIO) attended…

Published today in The New England Journal of Medicine, a multi-center phase I clinical study conducted across 11 countries, co-authored by Enriqueta Felip, Principal Investigator of VHIO´s Thoracic Tumors Group, represents an important step forward in the treatment of patients with ALK-rearranged lung cancer.